Skip to content

Longterm Intervention Study Allulose

Longterm Intervention Study Allulose - LisA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00028521
Enrollment
12
Registered
2023-05-03
Start date
2023-06-19
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

satiety, glucose metabolism, effects on microbiome

Interventions

Group 1: Daily consumption of three beverages containing Allulose for the duration of 4 weeks. The amount of allulose (g) corresponds to the amount of sucrose that would deliver 5.1% of the individual

Sponsors

Max Rubner-Institut
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: • BMI 18,5 – 30 kg/m² • No intended weight change • Good general Health • Written informed consent to participate in the study • No diseases that affect nutrient absorption, digestion, metabolism or excretion, especially malabsorption or indigestion of fructose • Clinical parameters for liver and kidney function, carbohydrate and fat metabolism and inflammation markers indicating absence of disease • No indication of restrictive eating behavior (Dutch Eating Behavior Questionnaire (DEBQ)) • Non- Smokers • No acute/regular intake of medication that affects fat or carbohydrate metabolism, or gastrointestinal tract • No intake of antibiotics in the prior 6 months • No pregnancy or lactation peroid • Absence of allergy / intolerance against any foods used in the study.

Exclusion criteria

Exclusion criteria: • Necessity to take certain medications during the study participation • Appearance of undesirable events • Appearance of acute diseases during the study participation • Revocation of consent to participate in the study • Non-compliance with the study protocol (including hygiene procedures)

Design outcomes

Primary

MeasureTime frame
Changes in postprandial concentrations of active GLP-1 in the plasma

Secondary

MeasureTime frame
• Postprandial plasma concentrations of gut hormones (GIP, PYY, CKK) • Postprandial changes in respiratory quotient • Blood glucose outcomes (Blood glucose, Insulin, c-Peptide, HbA1c, Matsuda Insulin sensitivity index, miRNA) • Metabolite profiles (including sugar profile) in stool, urine, saliva and serum • microbiome composition in stool, urine and saliva • Assessment of the capability of fecal bacteria to degrade Allulose, if applicable isolation, identification and characterization of these gut bacteria • Quantification of bacteria in feces that have the ability to degrade allulose. • Glut5 transporter expression • Excretion rate of allulose

Countries

Germany

Contacts

Public ContactStudienzentrum für Humanstudien

Max Rubner-Institut

Studienzentrum@mri.bund.de+49721 6625-400

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 21, 2026